Select a medication above to begin.
Harliku
nitisinone
Adult Dosing .
Dosage forms: TAB: 2 mg
alkaptonuria
- [2 mg PO qd]
- Info: start dietary restriction of tyrosine, phenylalanine if keratopathy occurs
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
Drug Interactions .
Overview
nitisinone
hydroxy-phenylpyruvate dioxygenase inhibitor
- CYP2C9 inhibitor, moderate
- OAT1 inhibitor
- OAT3 inhibitor
- CYP2E1 inducer, weak
Contraindicated
- deuruxolitinib
Avoid/Use Alternative
- abrocitinib
- bosentan
- erdafitinib
- etrasimod
- macitentan
- meloxicam
- methadone
- pirfenidone
- seladelpar
- siponimod
- sulbactam
Monitor/Modify Tx
- acetaminophen
- adefovir dipivoxil
- avatrombopag
- baricitinib
- carvedilol
- celecoxib
- ciprofloxacin
- clofarabine
- diclofenac
- fluvastatin
- fosphenytoin
- furosemide
- ganciclovir
- glimepiride
- glipizide
- glyburide
- methotrexate
- mycophenolate mofetil
- mycophenolic acid
- nateglinide
- pemetrexed
- phenobarbital
- phenytoin
- ruxolitinib
- torsemide
- vadadustat
- valganciclovir
- voriconazole
- warfarin
Caution Advised
- avibactam
- bumetanide
- cefaclor
- cefuroxime axetil
- cefuroxime sodium
- cephalexin
- dichlorphenamide
- dronabinol
- indomethacin
- ketoprofen
- meropenem
- ospemifene
- sulopenem
- tazobactam
- tenofovir disoproxil
- vaborbactam
Adverse Reactions .
Serious Reactions
- plasma tyrosine elevated
- keratitis
- corneal ulcer
- hyperkeratotic plaques
- leukopenia
- thrombocytopenia
Common Reactions
- plasma tyrosine elevated
- keratitis
- thrombocytopenia
- leukopenia
- conjunctivitis
- corneal opacification
- photophobia
- keratopathy
Safety/Monitoring .
Monitoring Parameters
ophthalmic exam incl. slit lamp exam at baseline, then regularly; plasma tyrosine, especially if ocular s/sx; CBC
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available; no known risk of teratogenicity based on animal data at up to 600x MRHD, though risk of incomplete skeletal ossification based on animal data at >12x MRHD
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; inadequate human data available to assess risk of infant harm; no human data available to assess effects on milk production
Pharmacology .
Metabolism: liver; CYP450: 3A4 (minor) substrate
Excretion: urine (3% unchanged); Half-life: 59.3h
Subclass: Inherited Metabolic Disorders
Mechanism of Action
inhibits 4-hydroxyphenyl-pyruvate dioxygenase, reducing urine homogentisic acid
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.